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INTRODUCTION
The etiology of multiple sclerosis (MS) remains
unknown, although the evidence for an autoimmune patho-
genesis is persuasive [1]. It is postulated that myelin pro-
teins, such as myelin basic protein (MBP), proteolipid pro-
tein (PLP), and perhaps myelin oligodendrocyte glycopro-
tein (MOG), are targeted by pathogenic CD4+ T cells [2-7].
The pathology shows a predominant T-cell response both
perivascularly and in the myelin lesion [8]. Cerebrospinal
ﬂuid and blood responses appear to be speciﬁc for major
myelin proteins and are major histocompatibility complex
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ABSTRACT
Multiple sclerosis (MS) is an immune-mediated disease that may be amenable to high-dose immunosuppression with
peripheral blood stem cell transplantation (SCT) in selected patients. Five MS patients (all women, ages 39-47 years)
received granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization, CD34 cell selection for T-cell
depletion, a preparatory regimen of busulfan (1 mg/kg  16 doses) and cyclophosphamide (120 mg/kg), and antithy-
mocyte globulin (10 mg/kg  3 doses) at the time of stem cell infusion. Days required to recover absolute neutrophil
count >500 were 12 to 14 and platelet count >20,000 were 17 to 58. Posttransplantation infectious complications in
the first year after SCT occurred in 3 of 5 patients, and 1 patient died at day 22 after SCT from influenza A pneumo-
nia. Neuropathologic study in this patient showed demyelinating plaques with surrounding macrophages but only rare
T cells. In 2 patients, MS flared transiently with G-CSF. Magnetic resonance imaging gadolinium enhancement was
present in 3 of 5 patients before transplantation and 0 of 4 after SCT. There were cerebrospinal fluid oligoclonal bands
at 1 year after SCT, similar to the pretransplantation assays. Sustained suppression of peripheral blood mononuclear
cell proliferative responses to myelin antigens occurred after SCT, but new responses to some myelin peptide frag-
ments also developed after SCT. In 1 patient, enzyme-linked immunospot (ELISPOT) assays done 9 months
after SCT showed a predominant T helper 2 (Th2) cytokine pattern. Neurological progression of 1 point on the
extended disability status scale was seen in 1 patient 17 months after SCT. Another patient who was neurologically
stable died abruptly 19 months after SCT from overwhelming S. pneumoniae sepsis. The remaining patients have had
stable MS (follow-up, 18 and 30 months). In summary, our experience confirms the high-risk nature of this approach.
Further studies and longer follow-up would be needed to determine the significance of new lymphocyte proliferative
responses after SCT and the overall effect of this treatment on the natural history of MS.
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(MHC) class II restricted, and individual cerebrospinal ﬂuid
responses appear to be epitope speciﬁc [9-13]. Autoreactive
T cells become activated (particularly in HLA-DW2 indi-
viduals) by “molecular mimicry” exposure to viral antigens
that resemble myelin epitopes [14], constituting a “break
from tolerance.” Activated T cells in the central nervous sys-
tem (CNS) stimulate expression of cytokines and adhesion
molecules on endothelial cells. With the recruitment of
additional lymphocytes and monocytes, demyelinating
plaques ultimately develop. Further support for an autoim-
mune pathogenesis has emerged from studies of experimen-
tal allergic encephalomyelitis (EAE), an animal model with
clinical and pathologic similarities to MS. As in MS, myelin-
speciﬁc autoreactive T cells can be shown to be important in
EAE [15,16].
There is extensive literature on cytokine production in
MS, including cytokines expressed in the MS plaque [17]. It
has been demonstrated that myelin-specific T cells have
pro- or anti-inflammatory cytokine profiles at different
stages of the disease [18]. Pro-inflammatory cytokines such
as tumor necrosis factor (TNF)- and interferon (IFN)-
are observed in the relapsing phase of the disease and may
be detrimental because of the upregulation of MHC class II
molecules on astrocytes and microglia [19]. In contrast, a
switch from a pro-inflammatory cytokine profile to an anti-
inflammatory (interleukin [IL]-4, IL-10, or transforming
growth factor [TGF]-) cytokine profile has been shown to
occur during remission [18] and is associated with lesion
resolution.
MS occurs at a prevalence rate of about 60 per 100,000
people and usually follows a remitting and relapsing pattern,
initially. However, about half of the patients eventually
develop progressive disease (secondary progressive MS).
Most MS treatment strategies have involved immunosup-
pressant or anti-inﬂammatory agents [20], including gluco-
corticoids, immunosuppressive drugs and agents (including
total lymphoid irradiation), and immunomodulatory agents
(such as IFN-). Cyclophosphamide has been shown to have
a modest effect on slowing the course of chronic progressive
MS [21], and cyclophosphamide/adrenocorticotropic hor-
mone infusions have been shown to signiﬁcantly decrease
peripheral blood CD4+ T cells in treated patients [22].
However, there is some disagreement over the beneﬁt of
cyclophosphamide [23], and long-term cyclophosphamide
treatment is not often used in MS because of oncological
risk. Azathioprine and low-dose oral methotrexate [24,25]
have also been shown to have a modest effect in retarding
progressive MS, as have cladaribine [26] and most recently
IFN- [27] and mitoxantrone [28].
Based on the understanding of the immunopathology of
the disease and the recognized, albeit modest, inﬂuence of
immunosuppressants at conventional dosages, investigation-
al studies with high-dose immunosuppression and autolo-
gous peripheral blood stem cell transplantation (SCT) have
been designed for selected patients with rapidly progressive
disease. There are 2 published studies on early experiences of
SCT in MS. Fassas et al. [29] reported on 15 patients condi-
tioned with BEAM (carmustine, etoposide, high-dose cyto-
sine arabinoside, and melphalan) and given antithymocyte
globulin (ATG) (without other T-cell depletion), and Burt et
al. [30] reported 6 transplantations using T-cell depletion
and total body irradiation (TBI) with cyclophosphamide as
the preparatory regimen. In the present article, we report
toxicity experience in an SCT protocol with busulfan and
cyclophosphamide conditioning and T-cell depletion. We
also report results of immunologic monitoring after SCT,
including evaluation of lymphocyte proliferation to myelin
antigens and cytokine production by peripheral blood
mononuclear cells.
MATERIALS AND METHODS
Patient Eligibility
To be eligible for this study, a diagnosis of deﬁnite MS
according to the Schumacher criteria was required [31].
Only patients with primary or secondary progressive disease
were eligible. For primary progressive disease, the protocol
required a course of at least 3 years. Further entrance crite-
ria included an extended disability status scale (EDSS) score
[32] of 5.5 to 7.5 with EDSS progression of 2.0 or more in
the last 2 years or an increase of 1.0 to 1.5 in 2 years with a
change in Kurtzke’s functional system categories of 1 point
in 2 or more categories or 2 points in 1 or more categories
over the preceding year. Other eligibility criteria included
abnormalities on a brain magnetic resonance imaging (MRI)
scan compatible with demyelinating disease, evidence of in
situ formation of immunoglobulin (Ig) in the cerebrospinal
ﬂuid (either elevated CNS IgG synthesis rate or demonstra-
tion of oligoclonal bands on agarose electrophoresis), failure
of corticosteroids or other recognized MS therapies, and no
cytotoxic immunosuppressive therapy for at least 3 months
before entry.
Harvesting and Cryopreservation of Stem Cells
Until the completion of stem cell collection, 10 µg/kg
per day of granulocyte colony-stimulating factor (G-CSF)
was administered intravenously or subcutaneously.
Apheresis was started on the ﬁfth day of G-CSF administra-
tion and continued on each subsequent day for a targeted
collection of 6.5  106 unselected CD34+ cells/kg were col-
lected. The G-CSF dose was reduced by 50% when the total
white blood cell count was ≥60,000/µL. Each apheresis col-
lection took place over 4 hours, or until a volume of 12 L
had been processed. CD34+ cells were then isolated using
the Baxter Isolex 300 System with the 9069 anti-CD34
monoclonal antibody, freshly prepared Dynal paramagnetic
microspheres containing sheep anti-mouse IgG for roset-
ting of the CD34 cells, and a nonenzymatic stem cell releas-
ing agent to separate CD34 cells from the paramagnetic
microspheres. Peripheral stem cells were cryopreserved fol-
lowing standard methods as previously described [33].
Preparatory Regimen and Supportive Care
Phenytoin prophylaxis for busulfan-associated seizures
was begun on day –12 and continued through day –2. Oral
busulfan (initial dose, 1 mg/kg) was given for 16 doses
between day –8 and day –4: 1 test dose on day –8 and 15 sub-
sequent doses every 6 hours starting on day –7. Busulfan
blood levels were obtained after the initial test dose (day –8).
If area under the curve (AUC) calculation was >1500 µmol/L
 min, busulfan doses 3-16 were adjusted according to the
formula [1200 µmol/L  min/ﬁrst dose AUC] times the ﬁrst
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dose. Doses were not reduced by any more than 20% of the
initial test dose. Cyclophosphamide (60 mg/kg of ideal body
weight) was infused intravenously over 1 hour on day –3 and
day –2, and mesna was given at 40% of the cyclophosphamide
dose over 15 minutes every 3 hours for a total of 48 hours
(beginning with the ﬁrst cyclophosphamide dose) to protect
against hemorrhagic cystitis. Equine ATG (Pharmacia &
Upjohn, Kalamazoo, MI) at 10 mg/kg actual body weight was
administered on day –1, day 0, and day 1 as an intravenous
infusion over 4 hours (after premedication with aceta-
minophen, diphenhydramine, and methylprednisolone).
All patients received a right atrial catheter before therapy.
Levoﬂoxacin was started after the ﬁnal busulfan dose, and
patients received prophylaxis with oral trimethoprim and
sulfamethoxazole or inhaled pentamidine on day –8 through
day –3. Heparin by continuous infusion (100 U/kg per day)
for veno-occlusive disease prophylaxis was given until day 21.
G-CSF at 5 µg/kg per day intravenously was administered on
day 1 and continued until the absolute neutrophil count was
>1000 for 3 consecutive days.
Evaluation of Disease Status
Patients were evaluated by neurological examination and
EDSS scores [32] during mobilization and throughout the
inpatient hospitalization for SCT. Then patients were fol-
lowed monthly for 6 months and every 2 months for the
remainder of the study, with a 3-year follow-up intended.
The EDSS range required by eligibility is inﬂuenced pre-
dominantly by ambulatory ability (EDSS 5.5: walk 100
meters but not 200 meters without aid or rest; EDSS 6.0:
need cane or brace to walk 100 meters; EDSS 6.5: need bilat-
eral assistance of canes, crutches, or braces to walk 20 meters;
EDSS 7.0: unable to walk >5 meters even with aids; EDSS
7.5: unable to take more than a few steps, may need help to
transfer). MRI scans including T2, Flair sequences, and
gadolinium enhancement were obtained pretransplantation
to conﬁrm eligibility and every 6 months after SCT for 3 years.
Cerebrospinal ﬂuid tests including evaluation for in situ CNS
formation of Ig were done pretransplantation and 1 year after
SCT. Before transplantation and at various times after SCT,
peripheral blood mononuclear cells were obtained for lym-
phoproliferative and ELISPOT assays.
Immunologic Assays
Immunohistochemical staining of deparafﬁnized sections
followed a published method [34]. For lymphoproliferative
assays, peptides corresponding to sequences of human MBP,
MOG, and PLP were synthesized at the University of
Southern California microchemical core facility. Peptide-
speciﬁc proliferation of peripheral blood mononuclear cells
(PBMCs) was assessed in a 96-hour assay measuring
[3H]thymidine incorporation. Briefly, purified PBMCs
were resuspended at 106/mL in X-VIVO 20 (Biowhittaker,
Walkersville, MD) supplemented with 100 U/mL benzylpeni-
cillin, 100 µg/mL streptomycin, and 10–5 mol/L -mercap-
toethanol. Aliquots of 100 µL of the PBMC suspension were
added to wells, in triplicate, in the presence of either optimal
concentrations of the different peptides, 10 µg/mL phy-
tohemagglutinin (PHA), or medium alone in ﬂat-bottomed
96-well plates. After G-CSF treatment and SCT, cell cul-
tures being assayed for proliferative responses were supple-
mented with 20 IU/mL recombinant human IL-2 for ampli-
ﬁcation of weak responses. The concentration of each pep-
tide that gave the maximal proliferative response over a wide
range of concentrations was determined in preliminary
experiments with PBMC from other patients. Cultures were
pulsed with 1 µCi per well of [3H]thymidine during the last
12 to 15 hours of the proliferation assay. The cells were then
harvested on glass ﬁber ﬁlter paper and counted in a scintil-
lation counter.
Antigen-speciﬁc ELISPOT assays were used to deter-
mine the number of antigen-speciﬁc lymphocytes that pro-
duced the cytokines IL-2, IL-4, IL-10, and IFN-. Brieﬂy,
105, 5  104, and 104 puriﬁed PBMCs were added, in a
100-µL volume, to wells of a 96-well microtitration plate
(Millipore, Bedford, MA) previously coated with an optimal
concentration of monoclonal antibody speciﬁc for each of
these cytokines. The following were added to at least 3 dif-
ferent wells of each cell concentration: 100 µL bovine MBP
(100 µg/mL), whole bovine myelin (200 µg/mL), PHA
(20 µg/mL), or medium. Cells and antigens were cultured
undisturbed for 40 hours. Each well was then washed exten-
sively with phosphate-buffered saline (PBS) containing 1%
fetal calf serum (FCS) and 0.1% Tween 20 and incubated
overnight with an optimal concentration of a biotinylated
monoclonal antibody speciﬁc for the same cytokine as the
monoclonal antibody used to coat the well. Each well was
then washed extensively with PBS containing 1% FCS and
0.1% Tween 20 and incubated for 60 minutes with an opti-
mal concentration of a streptavidin alkaline phosphatase con-
jugate. After further washes, the spots demonstrating anti-
gen-speciﬁc cells were developed using a colorimetric reac-
tion. The number of spots in each well was determined by
light microscopy.
RESULTS
Neurological Course Before SCT
Five subjects were entered into the protocol. All subjects
were women (ages 39-47 years) with secondary progressive
MS. Table 1 summarizes the neurological course of their dis-
ease before SCT. Patients 1, 2, 3, and 5 had fairly typical MS
courses with an age of ﬁrst symptom of 18 to 25 years, total
duration of remitting and relapsing phase of 11 to 22 years
(median, 14.5 years before entering the progressive phase),
and duration of progressive disease before SCT of 2 to
9 years. Initial symptom was visual loss in 2 patients (pars
planitis in patient 1 and optic neuritis in patient 2), brain
stem symptoms in patient 3, and cervical cord posterior col-
umn symptoms in patient 5. The MS diagnosis was made by
MRI scanning (and supported by cerebrospinal ﬂuid abnor-
malities in 3 patients) 11 to 22 years (median 13 years) after
the ﬁrst neurological symptom. Patient 4 had a much more
aggressive course than the others, with initial MS symptom
occurring relatively late at age 35, progressive disease begin-
ning at age 37 (with prominent cerebellar, upper motor neu-
ron, and cognitive difﬁculties), and SCT done at age 39. At
the progressive stage, all patients had signs of myelopathy,
and 3 had prominent upper motor neuron bladder symp-
toms. Three patients had courses of IFN- and 1 had been
on azathioprine. Four of the 5 patients were given a 3-day
course of methylprednisolone 1000 mg/day in the weeks
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before stem cell mobilization, and none showed neurological
improvement. The EDSS at the time of transplantation
ranged from 5.5 to 7.5 (ie, ambulatory without aid for about
100 meters in patient 5 and unable to take more than a few
steps in patient 4).
Toxicity During Stem Cell Mobilization
Patient 4 (transplantation date May 13, 1998) had a severe
MS ﬂare during G-CSF mobilization as manifested by right
hemiplegia. She was taken off the protocol and treated with
high-dose methylprednisolone 1000 mg/d for 5 days. There
was improvement in the hemiplegia to the pre–G-CSF base-
line. She was given cytotoxic drugs as therapy for her MS and
to facilitate completion of stem cell collection: etoposide (VP-
16) 1 g/m2 intravenously over 4 hours and cyclophosphamide
2 g/m2 intravenously over 2 hours. G-CSF was re-instituted
96 hours later. She was then treated with pulsed cyclophos-
phamide 250 mg/kg intravenously about every 4 weeks over
Figure 1. Magnetic resonance imaging with gadolinium enhancement in patient 4 before stem cell mobilization (upper row) and 4 months later
before conditioning for stem cell transplantation (SCT) (lower row). Because of worsening of multiple sclerosis signs during mobilization, the patient
was removed from protocol, given 1 g/m2 VP-16 (etoposide) and 2 g/m2 cyclophosphamide, and 96 hours later granulocyte colony-stimulating fac-
tor (G-CSF) at 10 µg/kg per day. Stem cell collection was then completed, and pulsed cyclophosphamide given approximately every 4 weeks for
4 months until BEAM (carmustine, etoposide, high-dose cytosine arabinoside, and melphalan) conditioning for SCT.
Table 1. Neurological Course Before Stem Cell Transplantation*
Age at Remitting and Progressive Disease
Onset, y Relapsing Age at Method of Age at Age at EDSS
(Symptom) Symptoms Diagnosis, y Diagnosis Treatment Onset, y Symptoms Transplantation, y score
Patient 1 25 Sensory loss 36 MRI IFN--1b 39 Leg weakness 41 6.0
(pars planitis) Facial spasm CSF Methylprednisolone Fatigue
Facial pain VEP
Spastic dysphonia
Patient 2 25 Imbalance 36 MRI Methylprednisolone 36 Leg weakness 45 7.0
(optic neuritis) Incoordination CSF Azathioprine Cognitive decline
UMN bladder
Patient 3 26 Sensory loss 39 MRI IFN--1b 41 Leg weakness 44 6.5
(diplopia) Optic neuritis CSF Methylprednisolone UMN bladder
Hemiparesis 
Patient 4 35 Sensory loss 35 MRI IFN--1b 37 Quadriparesis 39 7.5
(vestibular) Tonic spasms CSF IFN--1a Personality change
Diplopia Methylprednisolone Cognitive decline 
Hemiparesis Ataxia
Patient 5 18 Diplopia 40 MRI IFN--1a 40 Leg weakness 47 5.5
(Lhermitte’s) Methylprednisolone UMN bladder
*EDSS indicates Extended Disability Status Scale; MRI, magnetic resonance imaging; IFN, interferon; CSF, cerebrospinal ﬂuid; VEP, visual
evoked potential; UMN, upper motor neuron.
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the next 5 months before undergoing SCT. Multiple gadolin-
ium-enhancing lesions were present on this patient’s pre-
mobilization MRI, and all resolved before the SCT (Figure 1).
Because of the fragile state of this patient, the decision was
made to use BEAM, a conditioning regimen previously shown
to be safe in MS patients [29].
CD34+ and CD3+ Cell Collection and Engraftment
Data After T-Cell–Depleted Autologous SCT
Table 2 shows CD34+ and CD3+ cell collection data on
the Isolex device for the 5 patients. The median CD34+ cell
yield after selection was 66%, and T-cell depletion varied 2
to 4 logs. There were 50 to 167 times more CD3+ than
CD34+ cells before selection and 3 to 55 times more CD34+
than CD3+ cells after selection. In the most T-cell–depleted
patient (patient 1 in Table 2), 5  104/kg CD3+ cells
remained in the graft.
As shown in Table 3, the number of CD34+ cells used
ranged from 2.05 to 12.36  106/kg (median, 2.24  106
CD34+ cells/kg). The patient given cytotoxic drugs to com-
plete stem cell collection (patient 4) received 12.36  106
CD34+ cells/kg. None of the patients required busulfan dose
adjustment based on AUC calculations. An absolute neu-
trophil count of >500 was achieved by day 12 to 14 after
transplantation, and platelet count >20,000 was achieved by
day 17 to 58 (median, day 24.5). Patient 5 had slow graft
recovery; her platelet count did not reach >20,000 until day
58 and was 48,000 15 months after SCT. Requirements for
packed red blood cells ranged from 2 to 8 units (median,
5.5 units) and for platelets from 2 to 6 units (median, 4.5
units). CD4:CD8 ratios (reference range, 0.6-2.8) became
inverted after transplantation; eg, in patient 1, this ratio was
1.1 before transplantation, 0.2 at about day 80, 0.4 at day
150, and then within normal limits at 1 year after transplan-
tation. There was variability from patient to patient, with
depressed ratio of 0.48 at 1 year in patient 4 and a normal
ratio of 1.4 at 3 months in patient 3. Absolute lymphocyte
count ranged from 1.15  109/L to 1.76  109/L before
transplantation and 0.47  109/L to 1.08  109/L at 1 year
after SCT (with CD4+ cells accounting for 22% to 36% of
these lymphocytes at 1 year after SCT).
Infectious Disease Complications and Mortality
Table 4 summarizes toxicity and changes on neurological
follow-up. Three of the 5 patients had infectious complica-
tions in the ﬁrst year after SCT. Patient 2 died at day 22 of
inﬂuenza A pneumonia. Patient 3 developed staphylococcus
sepsis and pneumonitis related to a line infection on day 56
(treated successfully in the hospital), and patient 4 had
Clostridium difﬁcile enteritis 5 months after SCT. Another
death from infection occurred at 19 months after SCT. In
brief, patient 5 fell and fractured her hip 18 months after
SCT. Her leukocyte count at the time of the required surgi-
cal pinning of the hip was 4.5  109/L. As she was proceed-
ing satisfactorily with rehabilitation at home 19 months after
SCT, she developed respiratory symptoms that the family
initially interpreted as the ﬂu, but in 24 hours the illness pro-
gressed to the point where she could not get out of bed. She
was taken to a neighborhood hospital, where the leukocyte
count was measured as 0.4  109/L. Overwhelming sepsis
Table 2. CD34+ and CD3+ Cell Collection on the Isolex Device
CD34+ cells  106/kg CD3+ cells  106/kg
Preselection Postselection Yield, % Preselection Postselection Log depletion
Patient 1 9.19 2.73 30 420 0.05 4 logs
Patient 2 5.17 3.48 66 82 1.20 2 logs
Patient 3 3.07 2.05 66 368 0.29 3 logs
Patient 4 28.62 12.36 43 653 0.33 3 logs
Patient 5 3.68 2.83 77 489 0.19 3 logs
Table 3. Engraftment Data*
Preparatory CD34+ ANC Platelets Platelets Transfusions
Age, y Sex Mobilization Regimen Cells/kg,  106 >500, d >20,000, d > 50,000, d RBC Platelet
Patient 1 41 F G-CSF BU/CY 2.73 13 22 40 8 5
ATG
Patient 2 45 F G-CSF BU/CY 3.48 16 — — 12 31
ATG
Patient 3 44 F G-CSF BU/CY 2.05 14 27 27 7 2
ATG
Patient 4 39 F G-CSF BEAM 12.36 12 17 18 2 4
VP-16, CY ATG
G-CSF
Patient 5 47 F G-CSF BU/CY 2.83 12 58 450 4 6
ATG
*ANC indicates absolute neutrophil count; RBC, red blood cell; G-CSF, granulocyte colony-stimulating factor; BU/CY, busulfan and cyclophos-
phamide; ATG, antithymocyte serum; BEAM, carmustine, etoposide, high-dose cytosine arabinoside, and melphalan; VP-16, etoposide.
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with pneumonia was diagnosed, and Streptococcus pneumoniae
was isolated from blood and sputum. She died on the second
hospital day (and the fourth day of her acute illness) despite
antibiotics and reinfusion of backup stem cells collected at
the time of G-CSF mobilization.
Neuropathological Examination (Patient 2)
Neuropathological examination of the brain was done in
patient 2, who died on day 22 of inﬂuenza A pneumonia.
Multiple, small demyelinating lesions were noted grossly.
Luxol fast blue stain showed extensive demyelination in
these lesions (Figure 2A and E), and an axonal stain showed
a slight decrease in axonal density in the demyelinating
lesions (Figure 2B and F). Immunostaining showed exten-
sive labeling of macrophages (CD68+ cells as shown in
Figure 2C and G), whereas CD3+ immunostaining for
T cells (Figure 2D and H) was negative or showed only rare,
isolated T cells. Similarly, CD20+ immunostaining for
B cells was negative (data not shown). The round cells at the
edge of the demyelinating lesions that did not express
CD68, CD3, or CD20 were probably oligodendrocytes,
present in increased numbers.
Toxicity and Neurological Status After SCT
MRI gadolinium enhancement was present in the pre-
transplantation scan in 3 of the 5 patients, but gadolinium
enhancement has not been seen in any of the posttransplan-
tation scans obtained (Table 4).
In patient 1, improvement in fatigue occurred in the sec-
ond month after transplantation, and this improvement has
been sustained over follow-up. Hemifacial spasm also
resolved after SCT, and patient 1 increased independent
walking without further need for a cane or for left ankle-foot
orthotic. Although her degree of weakness and overall dis-
ability improved, the upper motor neuron abnormalities on
examination persisted. At 21 months after SCT, a recurrence
of spastic dysphonia developed and was treated with botu-
linum toxin injection,
Patient 3 was hospitalized in the early posttransplantation
course (day 27) with worsening of right hemiparesis. This
worsening occurred abruptly, temporally related to re-initia-
tion of G-CSF on day 25 for low white blood cell count. The
right hemiparesis improved to baseline after 3 days of methyl-
prednisolone 1000 mg/day. Subsequently, patient 3 devel-
oped no new neurological signs after SCT, but beginning at
15 months, the degree of weakness in her right arm was
worse than pretransplantation or the earlier posttransplanta-
tion examinations. At 17 months, the right leg weakness in
patient 3 progressed to the point that she was no longer
ambulatory (EDSS advanced from 6.5 to 7.5). The distribu-
tion and degree of weakness was similar to what was observed
during the transient worsening seen 27 days after SCT, but
there was no response this time to corticosteroids. A brain
MRI done at 17 months after SCT showed no gadolinium
enhancement and no increased burden on Flair or T2
sequences of demyelinating lesions compared with pretrans-
plantation MRI and scans done at 6 and 12 months after
transplantation. Because of the 1-point EDSS progression,
INF--1b was started in patient 3 at 1.5 years after SCT.
Patient 4 required help to transfer from wheelchair to
chair when she was seen for stem cell mobilization (EDSS
7.5) and then suffered right hemiplegia during G-CSF
mobilization as described above. There was improvement
following cytotoxic drug therapy, correlating with improve-
ment in MRI gadolinium enhancement (Figure 1), to the
point where she could walk 50 meters with her husband
standing in front and supporting both arms. By 3 months
after SCT, she could no longer do this because of right leg
weakness. Overall, her EDSS score was unchanged from the
initial evaluation at the time of protocol enrollment (EDSS
7.5). Patient 4 did show some improvement in attention
span and ability with cognitive tasks after SCT.
Patient 5, similar to patient 1, reported improvement in
fatigue after SCT. She remained neurologically stable after
SCT and functionally more active, working part-time as a
cashier in the family-run service station and walking for the
most part without a cane up until her hip fracture 18 months
after SCT.
Cerebrospinal Fluid Assays Before and After SCT
Patients 1 and 3 had lumbar punctures just before proto-
col accrual and 1 year after SCT. Figure 3 shows agarose
electrophoresis on these pretransplantation and 1-year post-
transplantation samples along with calculated CNS IgG syn-
thesis rate [35]. There were multiple oligoclonal bands both
before and 1 year after transplantation. Similarly, the CNS
Table 4. Toxicity and Neurological Follow-Up After Stem Cell Transplantation*
MRI Gadolinium Enhancement CSF Oligoclonal Infectious Neurological EDSS 
Pretransplantation Posttransplantation Bands (12 mo) Complications Complications Progression
Patient 1 None None (6, 12, 18, Present None None None (at 30 mo)
24 mo)
Patient 2 Present — — Influenza A pneumonia, — —
ARDS (death day 22)
Patient 3 Present None (6, 12, Present Staphylococcus sepsis, Transient hemiparesis, Progressed 6.5 to 
17 mo) pneumonia, day 56 day 27 (on G-CSF) 7.5 (at 17 mo)
Patient 4 Present None (3, 12 mo) ND Clostridium difficile enteritis, Hemiparesis with None (at 22 mo)
5 mo G-CSF mobilization
Patient 5 None None (6, 12 mo) ND Pneumococcal pneumonia None None (at 18 mo)
and sepsis (death 19 mo)
*MRI indicates magnetic resonance imaging; CSF, cerebrospinal ﬂuid; EDSS, extended disability status scale; ARDS, acute respiratory distress
syndrome; G-CSF, granulocyte colony-stimulating factor; ND, not determined.
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Figure 2. Photomicrographs of a demyelinating lesion in patient 2. Arrowheads mark the border of demyelination. The luxol fast blue myelin stain
(A, E) shows extensive demyelination and a well-demarcated junction with the adjacent white matter. An immunostain for neuroﬁlament protein (B, F)
shows relative preservation of axons in the plaque. The presence of macrophages concentrated at the plaque edge is shown by the CD68 immunostain
(arrows) (C, G). The paucity of associated T lymphocytes is shown by the CD3 immunostain (D, H). (Magniﬁcation A-D, 100; E-H, 400). Death
occurred at day 22 from inﬂuenza A pneumonia. Primary antibody for the neuroﬁlament protein was obtained from Ventana (Tucson, AZ) and for
CD3 and CD68 from Dako (Carpinteria, CA).
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IgG synthesis rates (reference range, 0-8 mg/dL) were
markedly elevated both before and after transplantation,
although the rate decreased at 1 year in patient 3.
Immunologic Assays
Figures 4 and 5 show the effect of SCT on PBMC pro-
liferative responses to MBP epitopes and to immunodomi-
nant peptides of MBP and PLP [2,3,5,6]. Before transplanta-
tion, there was stimulation >2 times that of the media control
in 4 of the 14 MBP epitopes and 1 of 5 immunodominant
peptides in patient 3; in none of the MBP epitopes or
immunodominant peptides in patient 4; and in 11 of 14 MBP
epitopes and 2 of 5 immunodominant peptides in patient 5.
The scales on the y-axis in Figures 4 and 5 were selected to
illustrate differences over time in lymphoproliferative
responses to myelin antigens; the PHA responses were off
the scale in all 3 patients. All the assays shown in the ﬁrst
columns of Figures 4 and 5 (pre-SCT) were done on PBMCs
Figure 3. Cerebrospinal ﬂuid agarose electrophoresis for oligoclonal bands and central nervous system immunoglobulin G synthesis rate before and
1 year after stem cell transplantation in patients 1 and 3.
Figure 4. Peripheral blood mononuclear cell (PBMC) proliferative responses to myelin basic protein (MBP) peptides before stem cell transplantation
(pre-SCT) and at various times post-SCT in patients 3, 4, and 5. To amplify proliferative responses, interleukin-2 was added to PBMC cultures in the
post-SCT assays. Assays shown in the ﬁrst column (pre-SCT) were done on PBMCs drawn before granulocyte colony-stimulating factor (G-CSF)
administration. In patient 5, the second panel (pre-SCT, post–G-CSF) was an assay on PBMCs drawn after 4 days of G-CSF, just before the ﬁrst stem
cell collection. The sequence of MBP peptides was as follows: (1) amino acids 1-12, (2) amino acids 9-20, (3) amino acids 13-24, (4) amino acids 33-44,
(5) amino acids 39-50, (6) amino acids 45-56, (7) Exon 2 (part A), (8) Exon 2 (part B), (9) amino acids 59-70, (10) amino acids 65-77, (11) amino acids
84-106, (12) amino acids 121-140, (13) amino acids 135-146, and (14) amino acids 142-163. PHA indicates phytohemagglutinin.
Pretransplantation
1 year
Posttransplantation
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drawn before G-CSF administration for stem cell mobiliza-
tion. To determine the effect of G-CSF on the proliferative
responses, a second assay was done on patient 5 after 4 days
of G-CSF administration, just before the ﬁrst apheresis for
stem cell collection. These assays, shown in the second panel
of the third row of Figures 4 and 5 (pre-SCT, post-G-CSF),
demonstrate suppression of the proliferative responses. By
ﬂow cytometry, the proportion of CD3+ cells in peripheral
blood is decreased by about 50% in patients on G-CSF.
However, when the PBMC number was increased in prolif-
erative assays to adjust for this decrease in CD3+ cells, there
was still marked suppression of the proliferative responses to
myelin antigens (data not shown).
After SCT, the proliferative responses to MBP and myelin
immunodominant epitopes were suppressed for at least 20
months, even with addition of IL-2 to the culture media to
boost these responses (Figures 4 and 5). PHA responses were
also suppressed post-SCT with a decrease from 22% to 78%
(not shown). In patient 3, just after a 1-point EDSS progression
17 months post-SCT, a new proliferative response >2 times that
of the control was demonstrated to the immunodominant PLP
peptide 104-117 (Figure 5), and a signiﬁcant response to whole
bovine myelin was also present (not shown). Earlier in patient 3,
a new proliferative response to MBP 1-12 (Figure 4) was noted
at 8 months after SCT, a time when there was no recognized
change in clinical disease; and similar new responses without
neurological worsening were noted in other MBP, MOG, and
PLP peptides at 3 months after SCT in patients 4 and 5.
These assays do not measure nonproliferative responses
that may be present; ie, there may be an increased production
of cytokine in response to a given myelin antigen but no pro-
liferative response to the same antigen. To evaluate the
cytokine proﬁle after SCT, ELISPOT assays were done in
patient 5 at 9 months. The results in Figure 6 show that a
large number of PBMCs produced the Th2 cytokines IL-4
and IL-10 speciﬁcally following stimulation with the mitogen
PHA, bovine MBP, or bovine myelin compared with the con-
trols. In contrast, the Th1 cytokines IL-2 and IFN- were
Figure 5. Peripheral blood mononuclear cell (PBMC) proliferative responses to myelin immunodominant peptides before stem cell transplantation
(pre-SCT) and at various times post-SCT in patients 3, 4, and 5. To amplify proliferative responses, interleukin-2 was added to PBMC cultures in
the post-SCT assays. Assays shown in the ﬁrst column (pre-SCT) were done on samples drawn before granulocyte colony-stimulating factor (G-CSF)
administration. In patient 5, the second panel (pre-SCT, post–G-CSF) was an assay drawn after 4 days of G-CSF, just before the ﬁrst stem cell col-
lection. Myelin immunodominant peptides include myelin basic protein (MBP) 84-106, MBP 142-163, proteolipid protein (PLP) 104-117, PLP 142-
153, and myelin oligodendroglial glycoprotein (MOG) 42-53. PHA indicates phytohemagglutinin.
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produced by far fewer cells speciﬁcally in response to antigen
or mitogen when compared with the controls.
DISCUSSION
Clinical MS ﬂares occurred in 2 patients on G-CSF,
after SCT in patient 3 and during mobilization in patient 4.
Both patients returned to baseline neurological examination
and level of function after 3 to 5 days of methylprednisolone
at 1000 mg a day. Two additional patients at other trans-
plantation centers have had clinical ﬂares while receiving
G-CSF [36]. There have been additional anecdotal reports
of G-CSF triggering cutaneous vasculitis and arthritis in
Felty’s syndrome [37,38], and neurological worsening was
noted in 2 patients with systemic lupus erythematosis who
received G-CSF because of leukopenia [39]. The mecha-
nism whereby G-CSF may worsen MS is unknown, but it is
interesting to note that G-CSF administration in normal
volunteers produced a 25-fold increase in plasma TNF-
[40], a pro-inﬂammatory cytokine known to be increased
with MS disease activity [41]. In patient 5 (Figures 4 and 5)
and in control subjects (not shown), we found that 4 days of
G-CSF administration suppressed rather than activated
PBMC proliferative responses to myelin antigens. This sup-
pression may be mediated by monocytes, found at 2-fold
higher amounts in peripheral blood after G-CSF and
reported to suppress alloantigen responses [42]. The obser-
vations of ﬂares associated with G-CSF has led to protocol
modifications using corticosteroids concomitant with
G-CSF during stem cell mobilization [36].
In reported cases of SCT for MS, conditioning therapy
has consisted of BEAM [29] or TBI [30]. Although neurotox-
icity in MS patients has not been noted from these condi-
tioning regimens, too few patients—particularly those with
highly active demyelinating disease—have been treated to
assure the safety of these or other possible conditioning regi-
mens. Severe exacerbation of chronic inﬂammatory demyeli-
nating polyneuropathy has been reported in rare patients
transplanted for hematologic malignancy [43,44]. The initial
deterioration in these patients occurred during conditioning
therapy that included TBI, and it has been speculated that
TBI may have induced an endogenous factor that enhanced
demyelination or in some way interfered with ongoing
remyelination. Whether similar exacerbations may occur in
CNS demyelinating disease is not known. However, in at
least 1 EAE model, transient short-term worsening of paresis
leading to death in some animals has been noted after TBI or
after nervous system irradiation, but not after busulfan and
cyclophosphamide administration [45]. It is also known that
radiation, even in low doses, primes astrocytes and microglial
cells to produce TNF- [46]. These considerations led to the
choice of chemotherapy rather than TBI conditioning in this
protocol. The BEAM regimen is less myeloablative and
immunosuppressive than either TBI or busulfan/cyclophos-
phamide; and although the well-known neurological toxicity
from high-dose cytosine arabinoside (HDAC) is cerebellar
and neuronal (Purkinje cell dropout), there are reports of
peripheral nervous system demyelination after HDAC [47],
including HDAC conditioning for bone marrow transplanta-
tion [48]. In contrast, the neurological toxicity noted with
high-dose busulfan (seizures in up to 10% of patients not
given prophylactic anticonvulsants) is reversible and probably
directed at neurons and not myelin.
In addition to marked systemic immunosuppression, con-
ditioning regimens for SCT in MS should ablate immune
cells in the CNS. Unlike cyclophosphamide, which is a strong
immunosuppressant drug, busulfan has been shown to readily
cross the blood-brain barrier, producing cerebrospinal-ﬂuid-
to-plasma drug ratios of 1 or more [49]. Although busulfan is
included in conditioning regimens for its myeloablative prop-
Figure 6. ELISPOT assay 9 months after stem cell transplantation (SCT) in patient 5 showing numbers of cells producing interleukin (IL)-4, IL-10,
IL-2, and interferon (IFN)- after stimulation with phytohemagglutinin (PHA), human myelin basic protein (MBP), and bovine myelin. Increased
production of IL-4 and IL-10 indicates a predominant Th2 cytokine response.
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erty [50], there is evidence in animal studies of lymphocyte
depletion from busulfan [51], and clinical studies of bone
marrow transplantation for hematologic malignancies are
compatible with an immunosuppressant activity of busulfan
[52,53]. In the neuropathological examination of patient 2,
the number of T cells was less than what would be expected
in a patient with active disease [54] (as indicated by gadolini-
um enhancement on the pretransplantation MRI), and B cells
could not be detected at all despite the high number of
macrophages at the periphery of the demyelinating lesions
(Figure 2). This result is compatible with an EAE study that
demonstrated the absence of encephalogenic T cells in the
CNS as early as 1 month after TBI and syngeneic transplan-
tation [55] and with a neuropathological examination in a
patient who died 7 months after SCT with TBI conditioning,
in which T cells were absent in the CNS demyelinating
lesions [56]. Evidence against full or long-lasting immune
ablation of the CNS comes from detection of cerebrospinal
ﬂuid oligoclonal bands and elevated CNS IgG synthesis rate
in patients 1 and 3 at 1 year after SCT (Figure 3). Spinal ﬂuid
examination earlier than 1 year was not done in these patients,
so it is not possible to know whether there was a decrease and
then reappearance of Ig or whether the treatment had no
effect on CNS Ig.
As shown in Figures 4 and 5, PBMC proliferative
responses to myelin antigens were suppressed after SCT for
at least 20 months. However, some proliferative responses
persisted, and new proliferative responses—not present in
assays before SCT—developed. New responses seen 3 to 8
months after SCT suggest that myelin autoreactive T cells
were either present in the patient before transplantation and
survived conditioning and ATG therapy or were present in
the graft and survived ATG therapy after SCT (or both).
Then there was activation of these T cells after SCT, pre-
sumably by contact with myelin antigens or cross-reacting
antigens. No symptoms or signs of MS disease activity
occurred in our patients at these early times, and it is uncer-
tain whether similar early activation of myelin-reactive T cells
may lead to MS progression. Although T-cell clones reactive
with myelin antigens can be generated from peripheral blood
in normal individuals, the number of myelin-speciﬁc T cells
is higher in MS [57,58], and epitope spreading for both MBP
and PLP epitopes has been seen in successive MS attacks
[18,59]. If it can be shown that myelin-reactive T cells are still
present in the graft and perpetuate MS disease activity, there
would then be a rationale for further T-cell depletion, specif-
ic purging of myelin-reactive T cells, or attempts to induce
posttransplantation tolerance.
Demonstration of a proliferative response at late times
after SCT, such as the response to myelin immunodominant
peptide PLP 104-117 at 20 months in patient 3 (and not pres-
ent before or 8 months after SCT), suggests the additional
possibility of autoreactive T cells derived from stem cells pres-
ent in the graft. Theoretically, DNA marking studies in MS
patients undergoing SCT may tell the origin of late-develop-
ing myelin-reactive T cells. Patient 3 progressed 1 point on
the EDSS scale at 17 months after SCT. Whether this pro-
gression is in any way related to the demonstrated new prolif-
erative responses to bovine myelin or to human PLP 104-117
in patient 3 is unknown. However, we show here that SCT
offers an opportunity to prospectively study the development
of myelin T-cell responses and potentially to determine asso-
ciations of the T-cell responses with clinical and MRI out-
comes in MS. Our results also demonstrate the difﬁculty in
eliminating myelin-reactive T cells with SCT.
Also of potential use in following MS patients after SCT
is the study of nonproliferative PBMC responses and corre-
lation of these responses to neurological outcome. In gener-
al, a predominance of Th1 or a pro-inﬂammatory cytokine
proﬁle is associated with MS disease activity; whereas a Th2
or anti-inﬂammatory response, as shown in the ELISPOT
assay on patient 5 at 9 months (Figure 6), is consistent with
disease quiescence [18,60]. Longitudinal ELISPOT is
planned in future MS patients accrued to this transplantation
protocol.
Entrance requirements for the present protocol and
other MS transplantation protocols are restricted to patients
with moderately severe to severe disability (EDSS, 5.5 to
7.5), and a progression of 1 to 2 EDSS points in the previous
1 to 2 years is required. Particularly as a result of this restric-
tion, the primary clinical study outcome (changes in EDSS
scores) is relatively insensitive and inﬂuenced almost exclu-
sively by ambulatory ability. To improve sensitivity for MS
trials, the use of composite measures [61] has been proposed
(in addition to the EDSS scale and serial MRI scans). The
composite measures include an ambulation index, 9-hole peg
test for upper-extremity function, and the paced auditory
serial addition test for information processing. Also recently
emphasized has been the occurrence of axonal loss as distinct
from the immune-directed myelin attack as a further cause of
MS disability [62]. The neuropathological examination of
patient 2 (Figure 2B and F) shows a minor degree of axonal
loss, and the lucent areas or black holes on the T1 sequence
MRI in patient 4 (Figure 1) are indicative of axonal loss.
Demonstration of gadolinium enhancement after SCT
would indicate immune activity and a failure of the immuno-
suppressant therapy. In the 4 patients followed for 18 to
30 months, we have not detected gadolinium enhancement
after SCT. It should be noted, however, that MRI scans were
generally done just every 6 months and that only 2 of these 4
patients had enhancement on their pretransplantation scan.
As previously discussed, an EDSS progression of 1 point
occurred at 17 months in patient 3, and new PBMC prolif-
erative responses to myelin antigens were noted on assays
done at 20 months. However, the MRI scan in this patient at
17 months failed to show gadolinium enhancement or other
MRI evidence of progression, and it is uncertain whether the
EDSS progression was related to an immune-mediated
attack on myelin or whether it resulted from a nonimmune,
progressive degenerative process of axonal loss in a previous-
ly involved area.
Our experience with 1 acute patient death from inﬂuenza
A pneumonia 22 days after SCT illustrates the high-risk
nature of this treatment. Transplantation-related mortality is
generally deﬁned as deaths occurring in the ﬁrst 100 days
[63]. It is uncertain to what extent (if any) the protocol treat-
ment contributed to the risk of pneumococcal sepsis in
patient 5 at 19 months after SCT. Patient 5 had slow marrow
recovery (Table 3), but the leukocyte count was normal in this
patient the month before the pneumococcal sepsis. In 1000
consecutive patients undergoing high-dose chemotherapy
with SCT for hematologic and nonhematologic malignancies
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in community cancer centers, treatment-related mortality was
3.4% [63]. It is unlikely that MS itself would appreciably affect
mortality of SCT, but the risk of infection is higher in the pro-
tocols used for MS and other autoimmune diseases because of
the T-cell depletion from the CD34+ cell selection and ATG.
We have modiﬁed these protocols to obtain serum antibody to
S. pneumoniae, H. inﬂuenza, and hepatitis B at 12 months and
to re-immunize patients depending on the adequacy of the
antibody titers.
Patient 5, up to the point of her death, was neurological-
ly stable, and patients 1 and 4 have not progressed on the
EDSS scale with follow-up now from 16 to 30 months. This
may be taken as a promising sign for patients 1 and 4.
However, MS natural history studies suggest cautious inter-
pretation of preliminary results of new treatment strategies.
For subjects at EDSS 6, natural history studies have shown
that it takes a mean of 3 to 3.5 years (median, 2-2.5 years) to
progress to EDSS 7, and an even longer interval time is
required to progress from 7 to 8 [64,65]. Moreover, selection
of patients for study who have had antecedent progression (as
is mandated by the US Food and Drug Administration in this
and other MS transplantation protocols) does not assure a
high rate of progression [65]. Viewed in this way, the MS
patients reported here must be followed longer before a con-
clusion is reached on possible efﬁcacy of this treatment.
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